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Vascular disease is the largest single cause of long-term ill
health and disability in the United Kingdom and dispro-
portionately affects socially disadvantaged populations
[1,2]. Providing effective self-management support is a
key policy focus which aims to improve the skills and
confidence of patients to manage their illness. However,
existing approaches to supporting self-management have
shown limitations, particularly with equivocal evidence in
outcomes for socially disadvantaged groups [3-5]. The
limitations of these approaches to self-management
support strategies are that they over-simplify the everyday
challenges faced by people living with long-term health
problems and have often overlooked the social and
structural barriers such as access to resources, identifying
needs appropriately, and the role of personal networks of
support [3,4,6,7].
The BRinging Information and Guided Help Together
(BRIGHT) intervention aims to address this implementa-
tion gap and recognizes a necessity for changes to be
made at the level of the patient, practice, organization and
community [7-12]. With a particular need to address the
interface between primary care and resources in the
community, the BRIGHT intervention intends to enhance
the effectiveness of self-management strategies by focusing
more on patient contexts and personal networks that are
centrally involved in the mobilization and deployment of
resources used in managing chronic disease [13].
The BRIGHT intervention aims to improve the care
and outcomes for people with vascular conditions, in
particular stage 3 CKD, by:
1. Providing patient information that incorporates both
clinical and lay-experiential knowledge.
2. Broadening the scope of self-management support to
address both social and clinical needs.
3. Linking patients’ needs and preferences to local
community resources.
4. Embedding strategies for self-management support
into existing approaches to the delivery of care for
patients with long-term conditions.
This approach builds on evidence that socially disad-
vantaged groups may benefit from interventions which
are lay-led and community-located [2,4] and builds on
evidence that social networks are implicated in self-care
support outside formal health services [6]. A shift in
emphasis from an exclusive focus on the individual is
required to one which includes a greater focus on the
mobilization of resources and interaction with aspects
of everyday life (for example, home, family, work,
leisure and friends). Therefore the aim of the
BRIGHT intervention is to elicit people's needs in
order to develop social support strategies that can beadded to existing evidence-based approaches to guided
self- management support [13].
Developing a patient information resource
The BRIGHT intervention aims to improve self-manage-
ment support for people with vascular disease by addres-
sing an identified gap in the provision of information for
patients with stage 3 chronic kidney disease (CKD) [14].
A self-management guidebook was developed for this trial
entitled ‘Keeping your Kidneys Healthy - a guide to help
you understand and manage the early stages of kidney
problems’. The development of the guidebook followed
principles which have been established as part of a whole
systems approach to the provision of self-management
support [8,15-18]. These are: lay informed experiences to
be given equal weight to medical and clinical informed
evidence; the inclusion of personal experiences and
anecdotes to bring the information alive and; information
which is based on patient’s expressed needs and actual
ways of managing and not on assumptions. Further
principles followed included: good design; use of plain
English; and use of clear diagrams, pictures and cartoons to
aid understanding. The content includes and acknowledges
areas of uncertainty or lack of evidence to encourage people
to think about how they currently manage their condition,
what they want to change, and plan how to make changes
by themselves using the support of family and friends or
working with their doctor or nurse.
Provision of meaningful information around stage 3
CKD may provide a platform for improved medicines
management and lifestyle change [19]. CKD is common,
is associated with lower socioeconomic status, and often
exists with other conditions such as hypertension, dia-
betes and ischemic heart disease [20-24]. CKD is an in-
dependent risk factor for cardiovascular disease and its
early recognition and treatment, targeted at reducing
blood pressure can prevent or delay progression and re-
duce the risk of cardiovascular disease and renal failure
[25,26]. However, stage 3 CKD is usually asymptomatic
and awareness of diagnosis is low [27].
Professionals have expressed concerns that disclosing
asymptomatic stage 3 CKD to patients may create
anxiety, particularly ‘in the ‘elderly’ and those in whom
clinical benefit is deemed less certain [14]. General
practitioners (GPs) and practice nurses may not always
disclose a diagnosis of CKD to patients as the condition
and its associated risks are considered difficult for
patients to understand [28]. Furthermore, most qualitative
studies on experiences of managing kidney disease have fo-
cused on end stage renal failure and dialysis [29,30]. Taking
these concerns into account, the BRIGHT intervention
aims to improve the delivery of vascular care through the
provision of an information resource as a key component
of a complex self-management intervention for patients
Table 1 Components of the BRinging Information and
Guided Help Together (BRIGHT) intervention
Evidence Component of the BRIGHT
intervention
Information can be an effective
platform for changing behavior
and can be improved by integrating
patient experience alongside medical
information about management
and treatment [4,15-17].
A kidney information guidebook
for people with stage 3 CKD.
Social prescribing has shown
encouraging results at improving
health outcomes, reducing social
isolation and improving the quality
of the clinical consultation [35].
A self-assessment questionnaire
which is linked to an interactive
website to tailor access to types
of community-based resources.
Socially disadvantaged groups
are more likely to benefit from
interventions that fit with patients’
existing adaptations and that
reduce social isolation and improve
access to resources [3-6,39].
A telephone consultation with
a support coordinator to guide
patients through the
questionnaire and website.
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to address a tendency to avoid information exchange
around CKD and the approach taken aims to avoid treating
stage 3 CKD in isolation but rather recognizes its
management in the context of everyday life and in which
maintaining health while living with multiple conditions
is the norm rather than the exception [31].
Broadening the scope of self-management support:
linking patients’ needs and preferences to local
community resources
The BRIGHT intervention draws on the notion of ‘social
prescribing’ which is a recent initiative embracing an
approach to support for people with long-term health
problems that links clinical, everyday and personal
contexts. Social prescribing is a link scheme between
primary care and the community and voluntary sector
which provides pathways for patients to access acceptable
and available community support [32-35]. There is some
evidence that this approach can reduce isolation in
patients, increase the confidence of patients to manage
their health and improve the patient-clinician consultation
by providing alternative community-based options of
support for patients, which are acceptable and tailored to
specific needs [32,34]. However uncertainties persist about
optimal ways to refer patients from primary care into
community and voluntary sector organizations because
clinicians are either unaware of existing services or are
unclear about how they meet the clinical needs of patients.
Embedding self-management support strategies into
current delivery of care
The BRIGHT intervention has been informed by
Normalization Process Theory (NPT), which provides a
framework to understand and address processes underpin-
ning existing delivery of care [36,37]. The study embraces
the concept of minimally disruptive medicine, which
focuses on improving health outcomes through provision
of services that are designed to enhance individual capacity
to manage health and reduce the burden of treatment on
people’s lives [38]. This approach includes prioritizing care
from the patient’s perspective, addressing coordination
between services, as well as acknowledging multimorbidity
in both the design of care delivery and development of an
evidence base. The BRIGHT intervention has therefore
been designed to build on dialogue between primary care
clinicians and patients.
The BRIGHT trial aims to provide evidence that a
complementary package of support for people with
vascular disease which targets both clinical and social
needs can broaden the scope of self-management support
by addressing problems related to social disadvantage
[33,34]. In summary, the BRIGHT intervention builds on
the evidence in Table 1.Our approach for the design and proposed evaluation
of the BRIGHT complex intervention follows guidance as
outlined by the Medical Research Council [40]. We are
developing an evidence base for the BRIGHT intervention
using a mixed methodology combination of a randomized
controlled trial (RCT), nested qualitative research and
economic evaluation.
Aims
The principal research question is: In patients with stage 3
chronic kidney disease, can a complex self-management
intervention to improve knowledge of CKD management
and promote links with local community resources improve
self-management capacity, health-related quality of life and
blood pressure control compared to care as usual?
Methods/Designs
Design overview
The study is a two-arm, patient-randomized, RCT.
Participants will be primary care patients registered
with general practices with an existing diagnosis of
stage 3 CKD. Participants will be allocated to one of
two groups: an intervention group or a control group.
The intervention group will receive the BRIGHT
intervention, to be delivered after a recent clinical
appointment with a GP or practice nurse. Participants
in the control group will receive care as usual from
their general practice and will be provided with the
guidebook and website link at the end of the trial.
Patient data will be collected at two time points: at baseline
(prior to group allocation and intervention delivery) and at
six months post-intervention. The reporting of this trial
follows the Consolidated Standards of Reporting Trials
(CONSORT) guidelines [41-43].
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Patients must have a clinical diagnosis of stage 3 CKD and
will be identified from disease registers at GP practices.
Patients must be able to communicate in English and there
will be agreement with practices that the patient is
appropriate to be recruited to the trial. Patients receiving
palliative care or who have reduced capacity to consent
will be excluded from the trial.
Inclusion criteria will be stage 3 chronic kidney disease
(both stages 3a and 3b).
Exclusion criteria will be: mental incapacity to provide
informed consent; inability to communicate in English;
receiving palliative care. Only one person per household
will be eligible for the study to avoid potential contamin-
ation between control and intervention patients.Intervention
The proposed intervention entails provision of:
1. A kidney information guidebook.
2. A PLANS booklet and access to an interactive
website with tailored access to local resources.
3. Telephone support from a dedicated peer support
worker (see Figure 1).Table 2 PLANS categories
Category Description
Well-being Groups, services and activities intended for
general well-being and social participationThe guidebook
The kidney information guidebook builds on previous
research conducted by the authors, which shows that
health information is an effective strategy to support
self-management and can be improved by incorporating
the views and experiences of patients with clinical guidance
about management and treatment [4,15-17,44].
Two focus groups of patients with stage 3 CKD were
conducted and were recorded, transcribed and analyzed.
The guidebook was then developed using the empirical
data and qualitative literature. It includes sections
on patient experience, self-management options and




PLANS booklet and 
interactive website to tailor 
access to local resources
3
Telephone support to guide 
participants through PLANS 
and tailor access to 
community support services 
Figure 1 BRinging Information and Guided Help Together
(BRIGHT) Intervention.living with long-term conditions. The guidebook also
includes basic information about the early stages of
kidney problems and how they are managed by the
health service. The development process included input
and feedback from clinicians on the clinical guidance
included in the guidebook.
PLANS booklet and website
PLANS (Patient-Led Assessment for Network Support)
is an intervention developed from empirical work con-
ducted by this center with patients with vascular disease
that aims to increase social contact and promote commu-
nity support and engagement by creating links with local
resources based on need and personal preference. PLANS
is a patient self-assessment tool which links patients with
vascular disease to relevant local health resources. PLANS
aims to support sustainable health choices by promoting
local resources that are both acceptable and accessible to
patients. The resources in the PLANS database fall into
one or more different categories (see Table 2).
Patients receiving the intervention will have access to
the PLANS website and a PLANS booklet will be
available for patients without internet access. Both the
website and the booklet contain the same information.
The telephone support facility will guide participants
through the PLANS questions and options on the database.
Telephone support
Self-management interventions built around structured
telephone support offer a mechanism to reach patients
who have poor access to health care. Evidence indicates
telephone-based support in patients with associated
vascular conditions improves patient outcomes, such as
social support [45,46], and reduces hospitalizations [47,48].(for example, hobbies and interest groups).
Health education Groups, services and activities that offer health
related advice, guidance and support such as
healthy eating or condition-specific support.
Practical support Groups, services and activities that offer everyday
practical support (for example, day care and adult




Groups, services and activities that offer support
and guidance for diet and healthy eating
(for example, slimming groups).
Exercise and physical
activity
Groups, services and activities that provide
opportunities to keep fit and participate in physical
activity (for example, sports clubs or walking groups).
Mobility Services that offer support for people with limited
mobility or have difficulty using public transport
(for example, shopping and delivery services).
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increasingly being used to offer telephone support
as an alternative form of support from that offered by
clinicians to reach disadvantaged populations and to
provide more efficient delivery of care [39,49,50]. Peer
telephone support may have potential as a cost-effective
intervention [51,52]. Evidence suggests that peer telephone
support produces better health outcomes including effects
on self-management behavior for patients with associated
vascular conditions [46,48,49,53].
As part of BRIGHT we will recruit peer volunteers
(or lay workers), to deliver structured telephone support
to all patients in the intervention group. Peer support
workers will participate in a three-hour training session
to clarify and review evidence-based content materials
required for effective structured telephone support
[49,54], and to clarify when and how to facilitate
appropriate referrals to local resources. To facilitate
training, peer support workers will develop a detailed
workbook and receive guidance on how to deliver the
intervention by telephone.
Patients in the intervention group will receive two
telephone calls from a dedicated peer support worker;
one call at one-week post-administration of the kidney
information guidebook and the PLANS booklet, followed
by another call at four-weeks post-intervention. A peer
support worker will guide the patient through options for
local organizations and activities using motivational
techniques over the telephone. Additionally, patients will be
able to discuss alternative options for maintaining general
vascular health, lifestyle and self-management support
(for example, diabetes-specific education programs) with
a peer support worker. Peer telephone support will be
made available (Monday to Friday) throughout the
course of the trial for ongoing contact by participants,
should they require further assistance in linking to
community resources.
Outcomes
All outcomes are at the level of the patient. The primary
end-point will be the six-month follow-up for patient
health outcomes and costs. The trial has three primary
outcomes: one clinical outcome of blood pressure control
(dichotomized as controlled versus not controlled) and two
patient-reported outcomes of 1) self-management ability,
and 2) health-related quality of life (see Additional file 1).
Secondary outcomes include additional measures of
self-management ability, health status, anxiety (general
and CKD-specific), loneliness, medication adherence, social
networks and social involvement. Information on service
utilization and resource use will also be collected for use in
a cost-effectiveness analysis (see below). Each patient will
complete a baseline questionnaire, and a follow-up ques-
tionnaire will be sent at six months (see Additional file 1).Study processes
We aim to recruit patients registered with general practices
in Greater Manchester, which participated in a renal
collaborative project established by the Collaboration
for Leadership in Applied Health Research and Care
(CLAHRC) for Greater Manchester [55]. A number
of these practices will be in areas of socioeconomic
disadvantage as identified by Index of Multiple Deprivation
(IMD) scores.
Patient recruitment and randomisation
Practices will be offered options for how to recruit
patients from their CKD disease register to the study.
These options will include:
1. Telephone contact will be made by a member of the
practice team to patients due to be seen for a
vascular disease review and/or if the GP or nurse
prefer, through raising the study at the end of the
consultation. These patients will be informed about
the BRIGHT trial and asked if their contact details
can be forwarded to the BRIGHT team for them to
be contacted for further information.
2. Patients due to be seen for a disease review will be
sent an invitation and information sheet by their
general practice and asked to return a form agreeing
to be contacted (see Figure 2).
Patients who agree to participate in the trial will be
sent Part 1 of the baseline questionnaire to be completed
prior to a meeting with a researcher. A researcher will
then arrange to meet with the patient at a time and place
convenient for them. Once consented, the researcher will
collect Part 1 of the questionnaire and then complete Part
2 of the baseline questionnaire with the patient. The
baseline questionnaire is divided in this way to reduce
the burden on participants at one time point. In addition,
some measures in Part 2 of the baseline questionnaire are
optimally delivered at a face-to-face interview because of
their relative complexity.
Following completion of the questionnaires, the clinical
trials unit will be contacted (by phone or online) and the
patient will be allocated to a trial arm via a minimization al-
gorithm (incorporating a random component) to maximize
balance between the two arms on key prognostic factors.
Minimization will be performed with respect to age,
smoking status and evidence of other vascular disease,
and will be stratified by practice. Allocation is centralized to
prevent the researcher from consciously or unconsciously
affecting the patient selection process. This approach will
prevent selection bias and will maximize the precision of
the treatment effect estimates by ensuring balance between
arms with respect to practice recruitment rates and the
minimization factors.
Practices recruited from CLAHRC CKD 
collaborative
Identify patients from CKD registers and contacted 
by post or telephone 
Follow up phone 
calls from practice 
or second postal 
invite as necessary
Intervention
Supported self management intervention. Kidney 
information guidebook with links to PLANS questionnaire, 
telephone and website 
Control
Usual care and offer of 
kidney information 
guidebook at end of trial
1 & 4 week proactive 
telephone support  
6 month follow up
Primary outcome
Postal (Option 2)
Send invitation and information 
sheet
Telephone (Option 1)
Member of practice team contacts 
patient in advance of, or at disease 
review
If patient agrees their contact  
details are passed to the research 
team
Research team contacts patient
If patient agrees to participate researcher arranges a meeting to complete baseline 
questionnaire (to be carried out following a disease review appointment with their GP 
or practice nurse) and randomised to control or intervention. Patient sent letter of 
confirmation, information sheet and Part 1 of baseline questionnaire in advance of visit 
Patient contacts 
research team
6 month follow up
Primary outcome
Figure 2 BRinging Information and Guided Help Together (BRIGHT) trial recruitment flow chart.
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maximize the precision of the estimates of the treatment
effects by ensuring balance between arms on the
selected key variables. Although observer bias does not
apply in this case, researchers are blinded to prevent any
chance of them consciously or unconsciously affecting
the patient selection process.
The patient will be informed of their allocation to
either control or intervention group immediately
after the baseline interview. If allocated to the inter-
vention the patient will be given a kidney informa-
tion guidebook, website information and the PLANS
booklet. They will be informed that they will receive
a phone call from a peer support worker in one
week to discuss the PLANS options in the booklet/
website. Practices will be informed of patient participation
in the trial.Sample size calculation
The study is designed to have 80% power to detect a
standardized effect size of 0.25 on the primary outcome
of self-management between the control and intervention
arms. This is a relatively small effect, but is in line with
most sizes of effect observed in our previous trials of
self-management interventions. Using an alpha of 0.05,
and assuming a correlation of 0.5 between outcome mea-
sures at baseline and follow-up (a conservative estimate),
and 25% attrition of participants, we will recruit 500
patients across both arms of the trial. We aim to recruit
16 to 18 practices and to recruit 28 to 32 patients from
each practice.
Analysis
For each of the outcomes, multilevel regression analysis
will be used to examine differences between trial arms.
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will be logistic regression; for continuous outcomes the
model will be linear regression. All analyses will follow
intention-to-treat principles and a pre-specified analysis
plan. Primary analyses will control for baseline scores and
the design factors (practice, age-group, smoking status, and
additional vascular disease). Where appropriate, sensitivity
analyses will be conducted (for example, treating all missing
BP data as failures; control for additional covariates;
bootstrapped P values for skewed outcomes). All analysis
will be undertaken using Stata version 12 (http://www.
stata.com) and an alpha level of 5%. In the case of missing
data values, we will apply mean imputation and regression
imputation where rates are low, and consider multiple
imputation where they exceed 10%.
Cost-effectiveness analysis
This evaluation will assess the cost-effectiveness of
self-management support compared with usual care.
Utilization and resource use
Resource use data from primary and secondary care
contacts will be collected using patient questionnaire at six
month follow-up. Questionnaires previously used in large
multicentre RCTs will be adapted to capture resource use.
Unit costs
Unit cost estimates from published data sources will
be applied to relevant resource use data collected
above (for example, cost of GP visit applied to the
number of GP visits) to generate a total cost per patient
(post-randomization).
Intervention costs
We will estimate the cost of developing and producing
the booklet and will also assess the time spent training
individuals in telephone support.
Measurement of effectiveness within the trial
For the trial-based economic evaluation, the measure of
effect will be the EQ5D [56]. EQ5D will be collected at
baseline and then at six months. This instrument can be
used to generate Quality Adjusted Life Years (QALYs). The
QALY will be calculated using the Area under the Curve
method and adjusting for baseline scores on the EQ5D. In
addition, regression analyses will be conducted to identify
other factors that may affect individual health state; these
may include age, gender and the patient’s primary
diagnosis.
Extrapolation to the longer term
Changes in Health Related Quality of Life may be identified
within the trial period, and if so, these will be identified as
part of the within-trial analysis. However, it is also likelythat some costs and consequences of the intervention will
occur after the completion of trial follow-up. Ideally, the
economic evaluation should consider all relevant costs over
an appropriate time horizon, and hence we will attempt to
build a model to establish the cost-effectiveness of the
intervention over the longer time horizon. The generation
of a longer term model depends on the existence of links
between short-term outcomes, such as BP control, and
longer term quality of life. A review of the literature will be
conducted to establish whether it is possible to make these
links and therefore populate the model. If it is feasible to
make links between short- and long-term outcomes, the
model will be used to generate costs and Quality Adjusted
Life Years (QALYs) over the appropriate time horizon.
Synthesis of costs and outcomes
If appropriate, cost and QALY data will be synthesized to
generate an Incremental Cost-Effectiveness Ratio (ICER)
where additional cost of the intervention is formally com-
pared with additional benefits. The ICER can be used to
inform the adoption decision. However, economic evalu-
ation is conducted under conditions of uncertainty, which
in this data will be represented using cost-effectiveness
acceptability curves (CEACs) generated through the use of
probabilistic sensitivity analysis. CEACs will plot the
probability of self-management support being cost-effective
for a range of threshold values of an additional QALY, and
will be presented for both the within-trial analysis and
(if feasible), the longer term model.
Missing data
The cost-effectiveness analysis will apply imputation
techniques to address the statistical issues related to the
presence of missing resource use and health outcome
data. Imputation of missing data will be conducted using
STATA software and will use recommended techniques
such as multiple imputation.
Sensitivity analysis
Several sensitivity analyses will be performed to determine
the robustness of the results to altering certain assumptions.
For example, alternative forms of imputation of missing
data could alter the assessment of cost-effectiveness.
Process evaluation
A process evaluation has been designed to complement
and provide additional information concerning the trial.
Details about the process evaluation and accompanying
qualitative study are included in Additional file 2.
Ethics
The trial has received full ethical approval from
the Health Research Authority (REC reference:
11/NW0855) and will be conducted in accordance
Blickem et al. Trials 2013, 14:28 Page 8 of 11
http://www.trialsjournal.com/content/14/1/28with the UK Departments of Health’s Research Govern-
ance Framework.
Participating practices will be reimbursed for their
time and patients will receive a small incentive for
participating in the trial. The trial will not disadvantage
patients in the intervention or control group in terms of
the care received from their GP practice.
Discussion
The BRIGHT intervention has been designed to improve
vascular health through provision of an information
resource for patients with stage 3 CKD and to broaden
the scope of self-management support by linking with
health-relevant community resources. This approach draws
on understandings that the hidden ‘work’ associated with
long-term condition management is often absorbed by
personal networks. Therefore, patients with limited
personal resources and who live in socially disadvantaged
circumstances disproportionately experience the extra
burden of living with chronic illness. The BRIGHT inter-
vention has been designed to utilize personal networks
and community contexts as a complementary strategy to
support self-management in order to target support more
effectively for socially disadvantaged populations.
Methodological considerations
To date, we are unaware of previous RCTs evaluating
interventions aimed at improving the delivery of care for
people diagnosed with stage 3 chronic kidney disease.
During the design of the trial, there were a number of
methodological issues that we needed to consider that
are pertinent to the current management of stage 3
CKD in primary care.
Minimally disruptive medicine
We recognize the potential for information about
chronic kidney disease to cause distress in patients.
Therefore, the concept of minimally disruptive medicine
has provided a framework for the trial design [38], which
has sought to reduce the potential for distress. Patients
will only be recruited into the trial if they have already
been diagnosed by their GP as having stage 3 CKD and
are already on a CKD disease register at their general
practice. In addition, in order to avoid disruption to
routine care, recruitment and six-month follow-up
have been aligned with recommended clinical practice
for patients with stage 3 CKD. Visits to patients for
recruitment will take place within approximately six
weeks of their routine 'disease review' appointment
with their GP or practice nurse. In doing so, the study
aims to build on rather than disrupt existing dialogue
between participants and their registered GP or nurse.
In addition to initial contact being made by the practice
concerning the research, this approach aims to providefurther opportunities for the potential participant to raise
any queries about the research with their registered health
practitioner in advance of a face-to-face meeting with a
member of the research team.The quality and outcomes framework
Over the past decade there have been changes to the
funding structure of UK general practice [57]. In 2004, the
Quality and Outcomes framework (QOF) was introduced.
Based on best available evidence, indicators of quality have
been assigned to certain long-term conditions. Practices are
then paid for achieving targets derived from these
indicators. Clinical information systems comprised of
disease registers and computer templates have been
developed to help professionals deliver such care.
CKD has been included within the QOF since 2006.
However, although people with stages 1 to 2 with
proteinuria are at higher cardiovascular risk than patients
with stage 3A and no proteinuria, with the exception of
diabetes, QOF only incentivises care for people diagnosed
with CKD stages 3 to 5 [20]. We recognize that provision
of appropriate information may be relevant for this group
of patients but for trial purposes in order to be confident
of recruiting patients with a recorded diagnosis, a decision
was made to limit recruitment to patients on general
practice CKD registers who have a diagnosis of either
CKD stage 3A or 3B.Registered prevalence of CKD
National QOF data indicates that although incentivised,
CKD stages 3 to 5 are frequently unrecognized [58];
hence we aim to recruit patients registered with general
practices in Greater Manchester that participated in a
renal collaborative project established by the Collaboration
for Leadership in Applied Health Research and Care
(CLAHRC) for Greater Manchester [55]. The aim of the
collaborative was to improve the identification of CKD
cases in primary care, to reduce the gap between the
achieved and expected prevalence of CKD on practice
registers by 50%, and for 75% of those registered CKD
patients to achieve NICE Blood Pressure (BP) targets by
July 2010. Therefore prevalence of CKD is likely to be
higher in ‘collaborative’ practices than in other practices
in Greater Manchester and closer to the expected
prevalence. Recruiting these practices within the trial will
increase the chances of recruiting sufficient numbers of
patients into the trial. Also, there is variation in the levels
of blood pressure control in these practices (between 51%
and 91% of patients achieving target BPs) [55]. However,
we recognize that in recruiting participants from these
particular practices, the levels of blood pressure control
may be higher in the study sample than in the general
population.
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and evidenced for vascular conditions such as diabetes and
heart disease but much less attention has been given to the
importance of chronic kidney disease in the context of
maintaining vascular health. The BRIGHT intervention
has been developed with the understanding that self-
management support is a key strategy for supporting
people with vascular disease but has a tendency to overlook
the importance of everyday life contexts and how these
influence the ability of people to manage their health.
Trial status
At time of submission the BRIGHT trial is in the process
of recruiting patients to the study.
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Additional file 1: Outcome measures. Details of the outcome
measures used in the trial [13,59-77].
Additional file 2: Process evaluation. Outline of the process
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